Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation

NCT01154387 is registered in ClinicalTrials.gov with Tolera Therapeutics, Inc as lead sponsor.

NCT NCT01154387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01154387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation
Lead sponsor
Tolera Therapeutics, Inc
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 31, 2010
Completion date
June 30, 2013
Enrollment
85 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease, renal transplant